Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Cash & Equivalents: 2016-2024

Historic Cash & Equivalents for Organogenesis Holdings (ORGO) over the last 7 years, with Dec 2024 value amounting to $135.6 million.

  • Organogenesis Holdings' Cash & Equivalents fell 32.43% to $63.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.7 million, marking a year-over-year decrease of 32.43%. This contributed to the annual value of $135.6 million for FY2024, which is 30.56% up from last year.
  • Latest data reveals that Organogenesis Holdings reported Cash & Equivalents of $135.6 million as of FY2024, which was up 30.56% from $103.8 million recorded in FY2023.
  • In the past 5 years, Organogenesis Holdings' Cash & Equivalents ranged from a high of $135.6 million in FY2024 and a low of $84.4 million during FY2020.
  • Its 3-year average for Cash & Equivalents is $114.0 million, with a median of $103.8 million in 2023.
  • Per our database at Business Quant, Organogenesis Holdings' Cash & Equivalents soared by 35.00% in 2021 and then decreased by 10.05% in 2022.
  • Yearly analysis of 5 years shows Organogenesis Holdings' Cash & Equivalents stood at $84.4 million in 2020, then spiked by 35.00% to $113.9 million in 2021, then declined by 10.05% to $102.5 million in 2022, then climbed by 1.33% to $103.8 million in 2023, then surged by 30.56% to $135.6 million in 2024.